San Francisco, CANCT06989112Now EnrollingIRB Ready

Endometrial Cancer Clinical Trial in San Francisco, CA

Access cutting-edge endometrial cancer treatment through this phase 3 clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access endometrial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related endometrial cancer treatment provided free

Apply for This San Francisco Location

Check if you qualify for this endometrial cancer clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Endometrial Cancer Study in San Francisco

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations.
Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed).
Participant must have primary advanced disease (Stage III/IV) or recurrent endometrial cancer and meet at least one of the following criteria:
Primary Stage III (per FIGO 2023) disease with measurable disease at baseline per RECIST 1.1 based on the investigator's assessment.
Primary Stage IV (per FIGO 2023) disease regardless of presence of measurable disease at baseline.
Recurrent disease regardless of presence of measurable disease at baseline.
Endometrial cancer with HER2 IHC expression of 3+ or 2+ by prospective central testing.
Endometrial cancer that is determined pMMR by prospective central testing.
Provision of an adequate FFPE tumor tissue sample for central HER2, MMR, and PD-L1 IHC testing.
Prior therapy:
No prior chemotherapy for the treatment of EC, except for one prior line of adjuvant/ neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if completed ≥ 6 months prior to signature of the main ICF. Prior trastuzumab in the adjuvant/neoadjuvant setting is allowed.
No prior exposure to antibody-drug conjugates or immune checkpoint inhibitors
Participants may have received prior radiation therapy for the treatment of endometrial cancer. Adequate treatment washout period is required
Participants may have received prior hormonal therapy for the treatment of endometrial cancer. Adequate treatment washout period is required
Left ventricular ejection fraction ≥ 50% within 28 days before randomization.
Adequate organ and bone marrow function within 14 days before randomization.
The participant is not considered a candidate for curative therapy in the judgment of the investigator. Key

Exclusion Criteria

Any severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardize compliance with the protocol.
Active or ongoing serious chronic gastrointestinal conditions associated with diarrhea, primary immunodeficiency, or non-infectious skin disease requiring systemic treatment.
Active or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs.
History of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
Lung criteria:
Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease \[COPD\], restrictive lung disease, etc.).
Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening.
Prior pneumonectomy (complete).
History of myocardial infarction or unstable angina within 6 months before randomization, or symptomatic congestive heart failure (NYHA Class II to IV), clinically significant arrhythmia, uncontrolled hypertension, cardiomyopathy of any etiology or history of myocarditis.
History of organ transplant or allogeneic stem cell transplant.
Spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases may be included in the study.
Evidence of any of the following infections:
Active tuberculosis
HIV infection that is not well controlled.
Active hepatitis B or C infection.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT06989112) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Endometrial Cancer Treatment Options in San Francisco, CA

If you're searching for endometrial cancer treatment options in San Francisco, CA, this clinical trial (NCT06989112) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all endometrial cancer clinical trials near you to find additional studies recruiting in your area.

More Endometrial Cancer Trials in San Francisco, CA

See all endometrial cancer clinical trials recruiting in San Francisco — not just this study.

Browse Endometrial Cancer Trials in San Francisco →

Browse More Trials by Condition

Endometrial Cancer TrialsEssential Tremor TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA